Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response in Psoriasis Bristol Myers Squibb (NYSE:BMY) has announced new five-year data from the POETYK PSO long-term extension (LTE) trial, evaluating Sotyktu (deucravacitinib) in adult patients with moderate-to-severe plaque psoriasis. The…
Samsung Bioepis Gains EC Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™) Samsung Bioepis Co., Ltd. has announced that the European Commission (EC) has granted marketing authorization for two denosumab biosimilars, OBODENCE™ (60 mg prefilled syringe) and XBRYK™ (120 mg vial), which…
MED-EL USA Gets FDA Approval for SONNET 3 Audio Processor MED-EL USA has announced the U.S. Food and Drug Administration (FDA) approval of its latest innovation, the SONNET 3 audio processor, designed for use with MED-EL cochlear implants. As the…
FDA Grants Full Approval to Deciphera’s ROMVIMZA™ (vimseltinib) for Symptomatic TGCT Ono Pharmaceutical Co., Ltd. has announced that the U.S. Food and Drug Administration (FDA) has granted full approval for ROMVIMZA™ (vimseltinib), a kinase inhibitor, for the treatment of adult…
UroGen Shares ENVISION Trial Subgroup Analysis on Tumor Burden and UGN-102 Response UroGen Pharma Ltd. (Nasdaq: URGN) announced results from subgroup analyses of the pivotal ENVISION study, assessing the impact of tumor burden and focality on the response to UGN-102,…
IMFINZI® Regimen Boosts Survival in Muscle-Invasive Bladder Cancer: NIAGARA Phase III Post-Hoc Analysis A post-hoc exploratory analysis from the Phase III NIAGARA trial has shown that AstraZeneca’s IMFINZI® (durvalumab), when administered perioperatively with neoadjuvant chemotherapy, significantly improves event-free survival (EFS)…
Cancer Breakthroughs: Veracyte’s Decipher Tests and GRID Tool at ASCO GU Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) highlight the clinical utility of…
CSL and Arcturus’ KOSTAIVE® Self-amplifying mRNA COVID-19 Vaccine Approved by European Commission CSL (ASX: CSL; USOTC: CSLLY), a global biotechnology leader, and Arcturus Therapeutics (Nasdaq: ARCT), a pioneer in self-amplifying mRNA (sa-mRNA) technology, have announced that the European Commission has…
Galderma’s Nemluvio® (Nemolizumab) EU Approval for Atopic Dermatitis and Prurigo Nodularis Galderma announced that the European Commission has granted approval for Nemluvio® (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio, a…
DaVita Inc. Q4 2024 Results DaVita Inc. (NYSE: DVA), a leading provider of dialysis services, has announced its financial and operational results for the fourth quarter and year ended December 31, 2024. Despite facing challenges throughout the year, DaVita achieved…